💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Congress should easily ratify North American trade deal: U.S. trade chief

Published 12/17/2019, 01:52 PM
© Reuters. FILE PHOTO: U.S.-Mexico-Canada Agreement (USMCA) signing in Mexico City?

WASHINGTON (Reuters) - The U.S. Congress should easily approve a revised North American trade agreement, and increased trade flows will raise U.S. gross domestic product by a third to a full percentage point, U.S. Trade Representative Robert Lighthizer said on Tuesday.

Lighthizer told Fox Business Network that concerns raised by Mexico over the weekend about a Washington's plan to monitor Mexican labor standards under the deal involved a "misunderstanding" and were now resolved.

Mexico, the United States and Canada last week agreed to revised terms for the United States-Mexico-Canada Agreement (USMCA) to replace the 1994 North American Free Trade Agreement (NAFTA).

The U.S. House of Representatives' Ways and Means Committee expects to vote on the legislation on Tuesday, with the full House to vote later in the week, congressional sources said.

Lighthizer said the revamped trade deal had strong support from U.S. farmers, businesses, organized labor and both Republicans and Democrats, adding, "It should pass with a big number."

He said the agreement would create up to 500,000 new jobs and set a template for future trade deals.

The top U.S. trade negotiator said it had been a "real slog" achieving concurrence on the trade agreement, but it would have real benefits for the U.S., Canadian and Mexican economies.

In addition to boosting manufacturing and agriculture, the trade deal would bring automotive jobs back to the United States, and provisions on the digital economy would set "the absolute gold standard" for digital trade and financial services.

Lighthizer expressed regret that he had been forced to remove provisions that required a 10-year exclusivity period for biologic drugs, but said the decision was needed to appease U.S. Democrats, who feared that would raise prices for some of the priciest drugs on the market.

"Clearly getting rid of the biologic provision was a step backwards, and it was a compromise," he said. "You know, there are consequences of the Democrats' control of the House. And that was necessary and I'm sorry about it."

© Reuters. FILE PHOTO: U.S.-Mexico-Canada Agreement (USMCA) signing in Mexico City?

However, U.S. law still provided 12 years of protection for such drugs, he said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.